chromium oxide - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	chromium oxide	go back to main search page
Accession:	CHEBI:48235	browse the term
Synonyms:	related_synonym:	Chromoxide; chromium oxides; oxides of chromium

show annotations for term's descendants Sort by:
Rat (75) Mouse (77) Human (80) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (75)

chromium trioxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate co-treated with Mercuric Chloride co-treated with chromium trioxide co-treated with nickel chloride co-treated with manganese chloride co-treated with ferric chloride] results in decreased expression of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

activating transcription factor 2

increases phosphorylation

chromium trioxide results in increased phosphorylation of ATF2 protein

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

catalase

decreases activity

chromium trioxide results in decreased activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
increases stability

Acetylcysteine inhibits the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [chromium trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]; chromium trioxide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 mRNA]; chromium trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]
chromium trioxide results in increased stability of CYP1A1 protein

PMID:16274885 PMID:17606337

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

heme oxygenase 1

increases expression
multiple interactions

chromium trioxide results in increased expression of HMOX1 mRNA
[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Acetylcysteine inhibits the reaction [chromium trioxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of HMOX1 mRNA]

PMID:16274885 PMID:17606337

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases phosphorylation

chromium trioxide results in increased phosphorylation of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

mitogen activated protein kinase 1

multiple interactions

chromium trioxide results in increased phosphorylation of and results in increased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Acetylcysteine co-treated with chromium trioxide] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]; [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased activity of NQO1 protein; [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased expression of NQO1 mRNA; [Tetrachlorodibenzodioxin co-treated with chromium trioxide co-treated with Buthionine Sulfoximine] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine inhibits the reaction [chromium trioxide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; chromium trioxide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

dichromium trioxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein binding family A member 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of APBA1 mRNA

NCBI chr 1:221,363,769...221,569,496
Ensembl chr 1:221,363,778...221,566,553

G

BAG cochaperone 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of BAG1 mRNA

NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075

G

BCL2 associated X, apoptosis regulator

affects expression

chromic oxide affects the expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

affects expression

chromic oxide affects the expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 2

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 4

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

caspase 3

increases activity

chromic oxide analog results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

increases secretion

chromic oxide analog results in increased secretion of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 22

increases secretion

chromic oxide analog results in increased secretion of CCL22 protein

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 3

increases secretion

chromic oxide analog results in increased secretion of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

increases secretion

chromic oxide analog results in increased secretion of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 7

increases secretion

chromic oxide analog results in increased secretion of CCL7 protein

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

creatine kinase B

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CKB mRNA

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

creatine kinase, M-type

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CKM mRNA

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

collagen type VI alpha 2 chain

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of COL6A2 mRNA

NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564

G

C-X-C motif chemokine receptor 4

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

DAB adaptor protein 2

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of DAB2 mRNA

NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476

G

erythrocyte membrane protein band 4.1-like 3

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA

NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607

G

EPH receptor A5

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPHA5 mRNA

NCBI chr14:23,653,393...24,020,129
Ensembl chr14:23,653,393...24,017,317

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

ERCC excision repair 2, TFIIH core complex helicase subunit

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC2 mRNA

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

G

ERCC excision repair 5, endonuclease

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC5 mRNA

NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472

G

FAT atypical cadherin 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of FAT1 mRNA

NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

GATA binding protein 6

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of GATA6 mRNA

NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532

G

growth differentiation factor 15

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GLI family zinc finger 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of GLI1 mRNA

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

HCK proto-oncogene, Src family tyrosine kinase

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of HCK mRNA

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

histone cluster 1 H2A family like 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of H2AC6 mRNA

NCBI chr17:42,707,954...42,708,420

G

inhibitor of DNA binding 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

inhibitor of DNA binding 2

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ID2 mRNA

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

insulin-like growth factor binding protein 7

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of IGFBP7 mRNA

NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314

G

interleukin 1 beta

increases secretion

chromic oxide analog results in increased secretion of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases secretion

chromic oxide analog results in increased secretion of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit beta 4

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of ITGB4 mRNA

NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of JUNB mRNA

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

LDL receptor related protein associated protein 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of LRPAP1 mRNA

NCBI chr14:75,651,371...75,663,380
Ensembl chr14:75,651,376...75,665,414

G

mitogen-activated protein kinase kinase 6

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen-activated protein kinase 4

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAPK4 mRNA

NCBI chr18:67,512,805...67,661,271
Ensembl chr18:67,512,807...67,661,842

G

mitogen-activated protein kinase 9

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAPK9 mRNA

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

megakaryocyte-associated tyrosine kinase

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MATK mRNA

NCBI chr 7:8,456,990...8,465,947
Ensembl chr 7:8,456,998...8,462,022

G

MCC regulator of WNT signaling pathway

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MCC mRNA

NCBI chr18:36,794,206...37,266,237
Ensembl chr18:36,798,372...37,266,819

G

MCF.2 cell line derived transforming sequence

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MCF2 mRNA

NCBI chr X:138,414,077...138,514,828
Ensembl chr X:138,409,256...138,514,446

G

mutS homolog 2

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MSH2 mRNA

NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938

G

metallothionein 3

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of MT3 mRNA

NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MYCN mRNA

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

nuclear factor I X

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of NFIX mRNA

NCBI chr19:23,355,388...23,450,360
Ensembl chr19:23,355,498...23,448,265

G

nth-like DNA glycosylase 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of NTHL1 mRNA

NCBI chr10:13,655,791...13,661,958
Ensembl chr10:13,655,785...13,661,957

G

phosphatidylinositol-4-phosphate 5-kinase type 1 beta

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of PIP5K1B mRNA

NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672

G

protein tyrosine phosphatase 4A1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of PTP4A1 mRNA

NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964

G

ret proto-oncogene

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of RET mRNA

NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176

G

serum/glucocorticoid regulated kinase 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SGK1 mRNA

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

solute carrier family 2 member 3

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SLC2A3 mRNA

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

superoxide dismutase 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

serine peptidase inhibitor, Kazal type 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SPINK1 mRNA

NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642

G

sarcospan

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SSPN mRNA

NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554

G

stomatin

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of STOM mRNA

NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:18,644,378...18,667,354

G

transforming growth factor, beta 2

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transmembrane 4 L six family member 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TM4SF1 mRNA

NCBI chr 2:141,456,950...141,466,146
Ensembl chr 2:141,453,310...141,466,146

G

tumor necrosis factor

increases secretion

chromic oxide analog results in increased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1B

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

TNF superfamily member 10

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

vimentin

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of VIM mRNA

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

Wnt family member 1

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of WNT1 mRNA

NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651

G

Wnt family member 2

multiple interactions

[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of WNT2 mRNA

NCBI chr 4:46,328,408...46,374,673
Ensembl chr 4:46,333,998...46,374,402

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19899
chemical entity	19897
molecular entity	19897
transition element molecular entity	17461
transition element coordination entity	11748
chromium coordination entity	5614
chromium oxide	75
chromium dioxide	0
chromium trioxide	8
dichromium trioxide	68
dioxidodiperoxidochromate(2-)	0
diperoxidochromium	0
oxidodiperoxidochromium	0
tetraperoxidochromate(2-)	0
tetraperoxidochromate(3-)	0
Path 2
Term	Annotations
CHEBI ontology	19899
subatomic particle	19897
composite particle	19897
hadron	19897
baryon	19897
nucleon	19897
atomic nucleus	19897
atom	19897
metal atom	18054
transition element atom	17598
d-block element atom	17593
chromium group element atom	7967
chromium atom	6825
chromium molecular entity	6798
chromium coordination entity	5614
chromium oxide	75
chromium dioxide	0
chromium trioxide	8
dichromium trioxide	68
dioxidodiperoxidochromate(2-)	0
diperoxidochromium	0
oxidodiperoxidochromium	0
tetraperoxidochromate(2-)	0
tetraperoxidochromate(3-)	0

paths to the root